Sandra Fontanals retweetledi

🫁 Our real-world data of Dato-DXd in pretreated metastatic NSCLC from an Expanded Access Program at #ELCC26
@ICO_oncologia
▪️Median PFS: 4.6 months
▪️Median OS: 9.4 months
▪️Manageable safety, consistent with prior trials
Bringing clinical trial signals into real-world practice!! Where evidence truly meets patients 🎯
With Dato-DXd, it’s not just data…it’s Dato that matters 😉
Thank you to my mentors @cribanec, Dr. Miguel Mosteiro and @NadalErnest! 👏🏼
@OncoAlert @OncoReporte
@myESMO @_SEOM @Larvol @Lung_Cancers @LungCancerRx


English


























